Physician profile
Suzan E House
NPI 1831132984
$31,542.25
in general payments reported to CMS, 2019-2025
31 companies · $2,607 in 2025
The $2,607 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,829 · 2021: $1,250 · 2022: $1,060 · 2023: $1,910 · 2024: $2,419 · 2025: $2,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,806 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,806.07 |
| Education | $129.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,360.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $8,106.84 | 2019-2025 | |
| Abbvie INC. | $2,517.41 | 2019-2025 | |
| Amgen INC. | $1,854.24 | 2019-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $1,051.71 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,041.45 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $679.00 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $576.75 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $546.78 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $540.47 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $386.89 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $276.60 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $265.36 | 2019-2025 | Gazyva, Actemra |
| Genzyme Corporation | $181.32 | 2019-2024 | |
| Fresenius Kabi USA, LLC | $140.32 | 2023-2025 | Idacio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $129.98 | 2021-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $124.31 | 2024-2025 | Acthar |
| Sobi, INC | $100.34 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $99.69 | 2019-2021 | |
| Sandoz INC. | $98.98 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $95.78 | 2019-2025 | Strensiq |
| Celgene Corporation | $88.49 | 2019 | |
| Scilex Pharmaceuticals INC. | $55.10 | 2024 | |
| Pacira Therapeutics, INC. | $44.80 | 2019 | |
| Almatica Pharma LLC | $41.15 | 2024-2025 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.79 | 2023 | Spevigo |
| Kiniksa Pharmaceuticals, Ltd. | $23.57 | 2023 | Arcalyst |
| Ani Pharmaceuticals, INC. | $22.25 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $22.24 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $20.82 | 2022 | |
| Hikma Pharmaceuticals USA | $15.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzan House listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.